絞り込み

16645

広告

「"Plimack ER "[Author]」の検索結果

129件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

Clinical implications of molecular subtyping in bladder cancer.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

First-line Immunotherapy in Metastatic Urothelial Carcinoma.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Update on perioperative systemic therapy for urothelial carcinoma.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
Sort by
※並べ替えは表示に時間がかかります